Every round on record, with the sources behind each and the investors on them.
Allogenetics offers innovative gene therapy solutions to modify donor organs, making them invisible to the recipient's immune system and eliminating the need for lifelong immunosuppression.
allogenetics.comHanover, GermanyBiotech
7 sources
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The source names additional corporate and private investors but does not identify them. The Hanover, Germany dateline does not establish headquarters.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Bridge Pre-Series A [ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $4.4M €3.8 million | 2026-09-09 | NBank Capital | No recent discussion |
7 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 7 sources The source names additional corporate and private investors but does not identify them. The Hanover, Germany dateline does not establish headquarters. | ||||
Allogenetics develops a one-time ex vivo gene therapy that modifies donor organs before transplantation to prevent rejection and reduce or potentially eliminate lifelong immunosuppression for transplant patients.
Transplant recipients face graft rejection and the burden and risks of lifelong immunosuppression; Allogenetics' organ-side, one-time ex vivo gene therapy aims to make donor organs less visible to the immune system while retaining immune competence. Its €3.8 million Pre-Series A will move ALG-115 through IND-enabling studies toward first-in-human lung-transplant trials after preclinical eight-year survival in a pig model without immunosuppressants, making the financing a bet on translating that signal into clinical therapy.
Checked against 8 sources on Oct 5